Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deal Details 14
Private Equity 14
Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14
Partnerships 15
Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17
ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19
Biogen’s Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23
Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 25
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32
Licensing Agreements 33
Swedish Orphan Biovitrum Enters into Licensing Agreement with Novimmune 33
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 34
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 35
TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 36
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 37
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 38
Debt Offering 40
Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For US$86 Million 40
Swedish Orphan Biovitrum AB – Key Competitors 41
Swedish Orphan Biovitrum AB – Key Employees 42
Swedish Orphan Biovitrum AB – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 45
Financial Announcements 45
Oct 31, 2018: Sobi publishes the report for the third quarter 2018 45
Jul 18, 2018: Sobi publishes the report for the second quarter 2018 46
Apr 26, 2018: Sobi publishes the report for the first quarter 2018 47
Feb 22, 2018: Sobi publishes its report for the fourth quarter and full-year 2017 48
Oct 25, 2017: Sobi publishes its report for the third quarter 2017 49
Jul 19, 2017: Sobi publishes its report for the second quarter 2017 50
Apr 28, 2017: Sobi publishes its report for the first quarter 2017 51
Feb 16, 2017: Sobi publishes its report for the fourth quarter and full year 2016 52
Corporate Communications 53
Aug 22, 2018: Swedish Orphan Biovitrum names Anne Marie de Jonge Schuermans as head of technical operations 53
Feb 26, 2018: Swedish Orphan Biovitrum Appoints Henrik Stenqvist As New Chief Financial Officer 54
Oct 06, 2017: Norbert Oppitz joins Sobi as new Senior Vice President, Specialty Care 55
Jun 07, 2017: Chief Operating Officer Alan Raffensperger to leave Sobi 56
May 04, 2017: Guido Oelkers Appointed President and CEO at Sobi 57
Apr 07, 2017: Theresa Heggie resigns from the Board of Directors and will not be proposed for re-election at Sobi’s annual general meeting 2017 58
Jan 09, 2017: CEO Geoffrey McDonough to leave Swedish Orphan Biovitrum 59
Product News 60
12/13/2017: Sobi Launches Orfadin (nitisinone) Ambassador Program to Support Patients and Caregivers Living with Hereditary Tyrosinemia Type 1 (HT-1) 60
11/27/2017: Sobi Receives Approval From Health Canada for Orfadin (nitisinone) Oral Suspension for the Treatment of HT-1 61
09/05/2017: Sobi Receives Approval From the FDA for Once-Daily Dosing Frequency of Orfadin (nitisinone) for the Treatment of HT-1 62
05/28/2018: FDA Accepts emapalumab Biologics License Application with Priority Review 63
05/17/2017: Orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1 64
04/17/2018: Sobi Receives Approval from Health Canada for Once-Daily Dosing of Orfadin (nitisinone) for the Treatment of HT-1 65
03/27/2017: Novimmune opens a Branch Office in Basel 66
03/07/2017: FDA approves in-use storage at room temperature for Orfadin capsules 67
02/27/2018: Sobi’s Orfadin (nitisinone) Receives Positive Reimbursement Recommendation for the Treatment of HT-1 from CADTH Canadian Drug Expert Committee 68
02/02/2017: Sobi obtains approval from the European Commission for new dosing frequency of Orfadin 69
01/04/2017: Health Canada Approves Orfadin Capsules for Treatment of Hereditary Tyrosinaemia Type-1 (HT-1) 70
Product Approvals 71
Mar 29, 2018: Novimmune submits Biologics License Application in the US for its lead drug emapalumab 71
Jan 23, 2018: FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA 72
Sep 05, 2017: Novimmune Receives Rare Pediatric Disease Designation from the FDA for its Lead Drug emapalumab 73
Jul 05, 2017: FDA grants SOBI003 Orphan Drug Designation for the treatment of MPS IIIA 74
Other Significant Developments 75
May 31, 2018: Sobi discloses payments to healthcare professionals and healthcare organisations to increase transparency 75
Apr 17, 2018: Sobi publishes 2017 Annual and Sustainability Report 76
Feb 28, 2018: Sobi Launches Enhanced Corporate Sustainability Initiative 77
Jun 05, 2017: Sobi Keeps the Partner Products Business Area as an Integral Part of the Company 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Swedish Orphan Biovitrum Plans to Sell Partner Products Business 14
Baylor Research Enters into Licensing Agreement with Swedish Orphan Biovitrum 15
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ravicti 16
Swedish Orphan Biovitrum Enters into Distribution Agreement with Horizon Pharma for Ammonaps 17
ModiQuest Research Enters into Agreement with Swedish Orphan Biovitrum 18
Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 19
Biogen’s Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 20
Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 21
Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 22
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Hyperion Therapeutics 23
Auxilium Pharma Enter Into Co-Development Agreement with Swedish Orphan Biovitrum For Xiapex 24
Exelixis Amends Distribution Agreement with Swedish Orphan Biovitrum for Cometriq 25
Exelixis Enters Into Distribution Agreement With Swedish Orphan Biovitrum For Cometriq 27
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Pharmaswiss 29
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 30
Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 31
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 32
Swedish Orphan Biovitrum Enters into Licensing Agreement with Novimmune 33
Swedish Orphan Biovitrum Enters into Licensing Agreement with Valeant Pharma 34
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 35
TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 36
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Only for Children Pharma For Neonatology Treatment 37
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 38
Swedish Orphan Biovitrum Announces Private Placement Of Senior Bonds Due 2017 For US$86 Million 40
Swedish Orphan Biovitrum AB, Key Competitors 41
Swedish Orphan Biovitrum AB, Key Employees 42
Swedish Orphan Biovitrum AB, Subsidiaries 43
List of Figures
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Swedish Orphan Biovitrum AB, Medical Devices Deals, 2012 to YTD 2018 11